HOUSTON, TEXAS, April 25, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market ("Nasdaq") on April 23, 2024, notifying the Company that it has regained compliance with...
https://youtu.be/dldPXZIcCkI Link to site HERE. ...
The new Gen-3 HALO™ Clarity 15 milliamp (mA) HOUSTON, TX, April 09, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL; NXLIW) today announced it has completed the...
New method of use patent covers key aspects of the technology that enable patients to receive treatment from the privacy of their own homesHOUSTON, TX, April 04, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL; NXLIW) today...
Previously served as Acting General Counsel to the Department of Veterans AffairsHOUSTON, TEXAS, April 02, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL; NXLIW), today announced the appointment of former Acting General Counsel to the Department of Veterans...
Collaborative Study involving the VA and UCSD achieved statistically significant decrease in PCS and PTSD symptoms versus control group The data supports the Company's strategy to offer military and civilian physicians a new tool to effectively treat mTBI without...
Mental Health Center Initially Focused on Treatment of Patients with Substance Abuse DisorderHOUSTON, TEXAS, March 14, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL; NXLIW) today announced that it has commenced sales of its second generation (Gen-2), 15...
Event hosted by the U.S. Army Medical Research and Development Command's (USAMRDC) Combat Casualty Care Research Program (CCCRP) Neurotrauma Portfolio and the Biomedical Advanced Research and Development Authority (BARDA) Attendees included many of the leading thought leaders and decision-makers...
Clinical study demonstrated clinically meaningful and statistically significant improvements in key sleep parameters, compared to adult patients treated with placeboData published in Journal of Psychiatric Research suggests that the Gen-2 tACS device may have...
Company's International Reach Expanding with Latest Regulatory ApprovalHOUSTON, TEXAS, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL; NXLIW) today announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device, has been granted regulatory approval by...